Several of these GSK-3β inhibitors have been evaluated in preclinical studies (e.g., 6-bromoindirubin-3′-oxime (6-BIO, 5), hymenialdisine (6), kenpaullone (7), alsterpaullone (8), cazpaullone (9), and SB216763 (10), Figure 7 and Table 1), and some of them showed promising CNS-related preclinical data, namely neuroprotection, decrease of τ phosphorylation, therapeutic benefits in AD, and schizophrenic models. Here, GSK3B is linked to Alzheimer disease.